{"id":"W4416391839","doi":"10.1016/j.annonc.2025.09.080","title":"LBA68 CCTG BR.31: Adjuvant durvalumab (D) in resected non-small-cell lung cancer (NSCLC): Final overall survival (OS) and minimal residual disease (MRD) analyses","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Canadian Cancer Society; Dalhousie University; Ottawa Hospital","funders":"Daiichi Sankyo Europe; National Cancer Institute; Eli Lilly Japan; MSD K.K.; Chugai Pharmaceutical; Chinese Society of Clinical Oncology; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Eisai; Daiichi-Sankyo; Seagen; Astellas Foundation for Research on Metabolic Disorders; Taiho Pharmaceutical; Boehringer Ingelheim Japan; International Association for the Study of Lung Cancer; BeiGene; AstraZeneca; Associazione Italiana di Oncologia Medica; Novocure; Pfizer; Incyte; Ono Pharmaceutical; Eli Lilly and Company; European SocieTy for Radiotherapy and Oncology; Bristol-Myers Squibb; American Society of Clinical Oncology; Regeneron Pharmaceuticals; Sanofi; Amgen","keywords":"Durvalumab; Overall survival; Adjuvant; Lung cancer; Disease; Survival analysis; Proportional hazards model; Lung","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005836491,0.0002724859,0.0006353299,0.0002567911,0.0001569906,0.0004196757,0.0003810532,0.0004822467,0.002371181],"category_scores_gemma":[0.0005415303,0.0001951615,0.0003484327,0.0002313083,0.000237235,0.0002957749,0.0001690081,0.0008003212,0.0006571143],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006209275,"about_ca_system_score_gemma":0.0006103264,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001644767,"about_ca_topic_score_gemma":0.004506688,"domain_scores_codex":[0.9997452,0.00006655535,0.00001896284,0.00005371774,0.00004154101,0.0000740144],"domain_scores_gemma":[0.9997929,0.00004342767,0.00003898255,0.00002196048,0.00001356169,0.00008922658],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4028253,0.006689139,0.1047385,0.0005553088,0.001393794,0.00125126,0.0001794622,0.003400475,0.1476672,0.0007596323,0.01230469,0.3182354],"study_design_scores_gemma":[0.09492644,0.2281482,0.567448,0.0002977051,0.003202499,0.005538441,0.0003179452,0.01716248,0.04501731,0.001193359,0.03657523,0.0001723599],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957448,0.001730111,0.0001869198,0.0002104755,0.00006179948,0.00006939714,0.0005200206,0.00004241069,0.001434082],"genre_scores_gemma":[0.9964998,0.0005140189,0.0004401606,0.0001873921,0.00003020284,0.00006032972,0.001128468,0.00001140743,0.001128326],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002371181,"threshold_uncertainty_score":0.007932425,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09800486052716045,"score_gpt":0.4299573125928187,"score_spread":0.3319524520656583,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}